Chronic Pain Management Articles & Analysis: Older
23 news found
The three-year $2.97 million Phase 2 STTR Study Grant through the NIH HEAL Initiative (Helping End Addiction Long-term) is providing funding specifically in the Development of KLS-13019 for Neuropathic Pain DOYLESTOWN, PA – May 25, 2022 – Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible ...
Key findings from the studies showed that while CBD and KLS-13019 were both effective in preventing the development of pain associated with CIPN, KLS-13019 was also able to reverse CIPN-related pain – while CBD proved ineffective in doing so. ...
(“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today that its CEO Dean Petkanas has issued a letter to its shareholders, providing commentary on the Company’s recently achieved milestones, updates on its research and financial positioning. ...
Cervos Medical has developed minimally invasive, highly efficient, and cost-effective solutions that treat a variety of musculoskeletal conditions including growing bone, preserving joints, and managing chronic ...
The three-year STTR Study Grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for Development of Therapies and Technologies Directed at Enhanced Pain Management and will provide funding specifically in the Development of KLS-13019 for Neuropathic Pain. ...
Nalu is a California-based company with miniaturized, commercially available neurostimulation implants for chronic intractable pain management. Nalu’s miniature implantable pulse generator (IPG) is 27 times smaller than the largest commercially available IPGs. ...
Nalu is a California-based company with miniaturized, commercially available neurostimulation implants for chronic intractable pain management. Nalu’s miniature implantable pulse generator (IPG) is 27 times smaller than the largest commercially available IPGs. ...
The three-year STTR Study Grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for Development of Therapies and Technologies Directed at Enhanced Pain Management and will provide funding specifically in the Development of KLS-13019 for Neuropathic Pain. ...
The three-year STTR Study Grant is funded through the NIH HEAL Initiative (Helping End Addiction Long-term) for Development of Therapies and Technologies Directed at Enhanced Pain Management and will provide funding specifically in the Development of KLS-13019 for Neuropathic Pain. ...
(“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces the formation of Dermique Incorporated (“Dermique”), a new wholly owned subsidiary to hold, manage, commercialize and market the intellectual property assets related to the ...
Based on the LOR technique, the EpiFaith® syringe is a physician-centered safeguard for epidural analgesia, which is indicated for painless labor, surgical anesthesia and chronic pain management. Compared with traditional practice that relies on the manual sense, EpiFaith® provides intuitive signal that tells anesthesiologists the arrival ...
(“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. ...
(“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract ...
(“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announces its Nalu micro-Implantable Pulse Generator (mIPG) was named the Implant and Tissue-Replacement device Gold Winner at the 2021 Medical Design Excellence Awards (MDEA). ...
“With this latest upgrade, we offer an expanded menu of therapy options to help people suffering with intractable chronic pain to better configure their therapies according to their preferences and within clinician-defined ...
Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. ...
The unresolved pain can impact all aspects of their lives, creating physical, emotional, social and financial hardships,” said Ilya Yuffa, president, Lilly Bio-Medicines. ...
Bexson Biomedical, Inc., a research-stage company developing dosing and delivery solutions for mental health and pain management indications, announced today the addition of medical device and combination product developer, Sheldon Moberg, to its senior leadership team. ...
Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann as President & Chief Executive Officer. ...
The completed study could lead to a Phase 2 grant and further advances Kannalife’s belief that KLS-13019 could become a viable drug candidate, and an alternative to opioids, as a treatment for patients suffering from CIPN, and chronic pain management. CIPN is a disabling pain condition that afflicts between 30-40 percent of ...